Dornase alfa during lower respiratory tract infection post-lung transplantation: a randomized controlled trial

Benjamin James Tarrant, Gregory Snell, Steven Ivulich, Brenda Button, Bruce Thompson, Anne Holland

Research output: Contribution to journalArticleResearchpeer-review

1 Citation (Scopus)

Abstract

Lung transplant (LTx) recipients are at risk of lower respiratory tract infection (LRTI), while altered physiology may lead to difficulty clearing sputum. Mucoactive agents alter sputum properties and facilitate mucociliary clearance; however, there are no randomized controlled trials (RCTs) studying this post-LTx. This RCT evaluated the safety and efficacy of nebulized dornase alfa during LRTI post-LTx. Inpatient adults with LRTI and abnormal sputum following bilateral sequential LTx were eligible. Participants received 5 ml of isotonic saline, or 2.5 ml of dornase alfa, nebulized once daily for 1 month followed by 2 months symptom diary. Primary outcome was lung clearance index (LCI2%). Secondary outcomes included spirometry, quality of life, readmission, length of stay, self-reported exacerbations, and adverse events at baseline, 1 and 3 months. Thirty-two participated, 16 in each group, baseline mean (SD) FEV1% 58 (22), median (IQR) length of stay 7 (5) days, time since LTx 3.49 (6.80) years. There were no significant between-group differences in LCI2% at any point (1 month mean difference −0.34, 95% confidence interval (CI) −1.57 to 0.89; 3 months −0.76, 95% CI −2.29 to 0.78, favoring dornase alfa). Secondary outcomes were not different between groups. These results do not support the routine use of dornase alfa during LRTI in LTx recipients.

Original languageEnglish
Pages (from-to)603-613
Number of pages11
JournalTransplant International
Volume32
Issue number6
DOIs
Publication statusPublished - 1 Jun 2019

Keywords

  • expectorants
  • humans
  • lung diseases
  • physical therapy modalities
  • respiratory therapy
  • sputum

Cite this